![Syngene International's Bangalore facility Syngene International's Bangalore facility](https://bsmedia.business-standard.com/_media/bs/img/article/2015-09/01/full/1441092861-5328.jpg?im=Resize,width=640)
Syngene International's Bangalore facility
Drugmaker Biocon on Tuesday divested a 5.4 per cent stake in its research arm Syngene International for a little over Rs 1,220 crore through an open market transaction.
According to bulk deal data available with the BSE, Biocon, the promoter of Syngene International, sold a total of 21,789,164 shares, amounting to a 5.4 per cent stake, in the company.
The shares were sold at an average price of Rs 560.04 apiece, a discount of more than three per cent to Monday's closing price of Rs 578.75 on the BSE.
At this price, the transaction size has been pegged at Rs 1,220.28 crore, the data showed.
The scrip of Syngene International has settled 2.38 per cent lower at Rs 565 apiece on the BSE.
ICICI Prudential Mutual Fund was among the entities that lapped up the company's shares.
As of June year, of the promoters' holding of 70.29 per cent, Biocon held a 69.99 per cent stake in Syngene, the shareholding pattern with the exchange showed.
In separate block deals, Raja Ganesan Chandramogan, promoter of Hatsun Agro Products, offloaded 27.2 lakh shares of the company for nearly Rs 269 crore.
The shares were picked up by Sundaram Mutual Fund and SBI Mutual Fund.
(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)
Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.
As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.
Support quality journalism and subscribe to Business Standard.
Digital Editor
First Published: Tue, September 06 2022. 20:16 IST